We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A proposed class action suit alleging that multiple pharmacy benefit managers are responsible for Mylan’s price hike of EpiPen will move forward, after a Minnesota federal judge denied requests to have the case thrown out. Read More
Sen. Claire McCaskill (D-Mo.) released a third report on drug pricing claiming her constituents pay up to 600 percent more than citizens of other countries for branded Medicare Part D drugs. Read More
Eagle argued in favor of broad exclusivity for its product, writing that it should apply to any applications containing bendamustine for the indications protected by the orphan exclusivity. Read More
The expert panel also issued a positive opinion for Bevespi Aerosphere, AstraZeneca’s maintenance treatment for chronic obstructive pulmonary disease. Read More
The state of Kentucky has filed a lawsuit against Teva, alleging the drugmaker’s off-label promotion of two drugs for cancer pain has exacerbated the opioid epidemic. Read More
Abbott Laboratories and AbbVie reached a $25 million settlement with the federal government, which charged the companies violated the False Claims Act to promote sales of the drug TriCor (fenofibrate). Read More